Portal Hypertension - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Portal Hypertension - Pipeline Review, H1 2016', provides an overview of the Portal Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Portal Hypertension - The report reviews pipeline therapeutics for Portal Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Portal Hypertension therapeutics and enlists all their major and minor projects - The report assesses Portal Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Portal Hypertension Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Portal Hypertension - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Portal Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Portal Hypertension Overview 6 Therapeutics Development 7 Pipeline Products for Portal Hypertension - Overview 7 Portal Hypertension - Therapeutics under Development by Companies 8 Portal Hypertension - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Portal Hypertension - Products under Development by Companies 11 Portal Hypertension - Companies Involved in Therapeutics Development 12 Conatus Pharmaceuticals Inc. 12 Galectin Therapeutics, Inc. 13 Gilead Sciences, Inc. 14 Intercept Pharmaceuticals, Inc. 15 LinXis B.V. 16 Mezzion Pharma Co. Ltd. 17 Ono Pharmaceutical Co., Ltd. 18 Portal Hypertension - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 emricasan - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 GRMD-02 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 GS-9674 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 LIN-003 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 obeticholic acid - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ONO-1266 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 udenafil - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Portal Hypertension - Recent Pipeline Updates 42 Portal Hypertension - Dormant Projects 64 Portal Hypertension - Discontinued Products 65 Portal Hypertension - Product Development Milestones 66 Featured News & Press Releases 66 Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting 66 Sep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis 67 Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 68 Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 69 Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 70 Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting 71 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Number of Products under Development for Portal Hypertension, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Portal Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H1 2016 12 Portal Hypertension - Pipeline by Galectin Therapeutics, Inc., H1 2016 13 Portal Hypertension - Pipeline by Gilead Sciences, Inc., H1 2016 14 Portal Hypertension - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 15 Portal Hypertension - Pipeline by LinXis B.V., H1 2016 16 Portal Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H1 2016 17 Portal Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Portal Hypertension Therapeutics - Recent Pipeline Updates, H1 2016 42 Portal Hypertension - Dormant Projects, H1 2016 64 Portal Hypertension - Discontinued Products, H1 2016 65
List of Figures
Number of Products under Development for Portal Hypertension, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Top 10 Targets, H1 2016 20 Number of Products by Stage and Top 10 Targets, H1 2016 20 Number of Products by Top 10 Mechanism of Actions, H1 2016 22 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 22 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26
Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to moRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...
Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected toRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.